Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1582MR)

This product GTTS-WQ1582MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1582MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15670MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ2192MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ12586MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ8670MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ12324MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ10280MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ4426MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ272MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW